Arjun Balar reports on EV-201 results suggesting that cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer may benefit from treatment with enfortumab vedotin after checkpoint inhibitor therapy (4:14).
This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany.